Reinforcing Our Pipeline in Specific Fields through Alliances

The Kyorin Group has set a goal of establishing a strong presence in the specific fields of respiratory medicine, urology, and otolaryngology, and is working to reinforce its R&D pipeline. As the global supply of promising new drugs runs dry, the presence of competitors makes it extremely difficult to license in new products.

Under those difficult conditions, in the three years since fiscal 2008, we have been able to license three new products in the franchise customer field, including KRP-108, an inhaler for asthma, KRP-209, a treatment for tinnitus, and KRP-AB1102, a treatment for chronic obstructive pulmonary disease. These results are due to the fact that all of the companies licensing these products found the prospect of working with the Kyorin Group attractive, and were confident that we would prove to be a reliable partner. We believe this is evidence that the franchise customer strategy we are pursuing is gaining a firm hold in the pharmaceutical industry, both in Japan and overseas.

Going forward, our employees will work together to increase our comprehensive potential and build an even more attractive pipeline of products.

Promoting Domestic and Overseas Alliances

Through proactive collaboration with outside firms, the Kyorin Group is working to enrich our R&D pipeline and to maximize the value of our original products.